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Abstract: The synthesis and characterization of a new class 
of DOTA (1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-
tetraazacyclododecane) monoamide-linked glycoconjugates 
(glucose, lactose and galactose) of different valencies 
(mono, di and tetra) and their SmIII, EuIII and GdIII complexes 
are reported.  
The 1H NMR spectrum of EuIII-DOTALac2 shows the predominance 
of a single structural isomer of square antiprismatic 
geometry of the DOTA chelating moiety and fast rotation about 
the amide bond connecting to the targeting glycodendrimer. 
The in vitro relaxivity of the GdIII-glycoconjugates was 
studied by 1H nuclear magnetic relaxation dispersion (NMRD), 
yielding  parameters close to those reported for other DOTA 
monoamides.  
The known recognition of sugars by lectins makes these 
glycoconjugates good candidates for medical imaging agents 
(MRI and gamma scintigraphy). 
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Introduction 
 The number of suitable radiometals for use in nuclear 
medicine (both in diagnosis and in therapy) is considerable 
(γ-emitters like 111In or 67Ga; positron emitters as 68Ga or 
64Cu, and particle emitters like 90Y, 177Lu ( β-emitter) or 213Bi 
(α-emitter)).[1-4] However, the central question in the 
development of new radiopharmaceutical agents is how to 
deliver them specifically to the cellular targets 
(receptors). Many strategies have been attempted and some are 
currently in clinical use. The general strategy in the field 
of gamma-imaging is based on the use of radio-labeled 
conjugates that bind to specific receptors that are 
overexpressed in certain regions or organs in the body. 
Specific carriers like monoclonal antibodies [5] and peptides 
[6] proved, so far, to be the most successful approaches. The 
moiety of the conjugate that encapsulates the radio metal is 
a bifunctional chelator which simultaneously presents a 
functionality (usually carboxylic and amine groups) suitable 
for covalent binding to the carrier agent. 
Magnetic resonance imaging (MRI) is a diagnostic modality 
based on the enhancement of contrast given by paramagnetic 
contrast agents (CAs). GadoliniumIII chelates demonstrated to 
be the most suitable paramagnetic CAs for MRI, due to the 
high paramagnetism of the GdIII ion (4f 7) and to its slow 
electron spin relaxation. The efficiency of a MRI CA is based 
on its ability to selectively reduce the water proton 
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relaxation times of normal and lesioned tissues in the body, 
and is expressed by its relaxivity, r1 (in units of mM-1s-1). 
The relaxivity is defined as the longitudinal relaxation rate 
enhancement of the water protons for 1 mM concentration of 
paramagnetic compound.[7,8] 
Nowadays molecular imaging is a field of fast rising 
interest. [9] The main requisites in molecular imaging using 
MRI are high relaxivity and high biospecificity, in order to 
deliver as many paramagnetic species as possible to the 
receptors of interest and thus obtain images of the targeted 
cells. 
For the detection of hepatic lesions there are a few 
hepatocyte-specific MRI CAs which are lipophilic or 
amphiphilic compounds: [Gd(BOPTA)(H2O)]2- (BOPTA = 4-carboxy-
5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-
trazatridecan-13-oic acid) [10], [Gd(EOB-DTPA)(H2O)]2- (EOB-
DTPA = (S)-N-[2-[bis(carboxymethyl)amino]-3-(4-
ethoxyphenyl)propyl]-N-[2-
[bis(carboxymethyl)amino]ethyl]glycine)[11], [Mn(DPDP)(H2O)] 
(DPDP = N,N’-1,2-ethanediylbis-[N-[[3-hydroxy-2-methyl-5-
[phosphonooxy)methyl]-4-pyridinyl]methyl]glycine])  [12], 
superparamagnetic iron oxides [13], liposomal [14]  and 
micellar [15]  paramagnetic systems. 
The focus of our ongoing research plan is the synthesis 
of multivalent glycoconjugates of metal complexes as 
potential agents for medical imaging (MRI and scintigraphy). 
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These compounds include two different moieties: a metal 
chelator capable of forming chelates with lanthanideIII ions 
with high kinetic and thermodynamic stability, and a sugar 
moiety capable of interacting with high affinity and 
selectivity with endogenous lectins. [16]  Lectins are a large 
group of carbohydrate binding proteins broadly found in 
nature (including plants, animals and lower organisms). The 
lectin-carbohydrate interaction controls many biological 
events (immune function, fertilization, infectious cycles, 
metastasis, etc). [17] The effect of the valence of synthetic 
and natural glycoconjugates on the affinity to lectins has 
been fully demonstrated, although the physical nature of the 
phenomenon is still debatable. [18] A critical feature in the 
glycoconjugate-lectin interaction is the topology of both the 
glycoconjugate and lectin. In this respect, the relative 
orientation and spacing of the carbohydrate residues in the 
glycoconjugate in relation to the distribution of the 
Carbohydrate Recognition Domains (CRDs) on the lectins is of 
fundamental importance. [18,19] The hepatocyte cells on liver 
express lectins that recognize terminal β-galactosyl residues 
on desilylated glycoproteins-  asialoglycoprotein receptor 
(ASGPR).[20]  The targeting of endogenous lectins for drug 
delivery is an appealing concept. [21] The ASGPR can be 
targeted by attaching galactose residues to a desired carrier 
containing efficient reporter groups.[22-26] The pioneering 
work of Lee and others has demonstrated that the order of 
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increasing affinity (in vivo and in vitro) of multivalent 
glycoconjugates for the ASGPR is tetra>tri>di>mono.[52]   
The targeting of the ASGPR has been demonstrated both in 
a cell line and mice with a 111In-radiolabelled 
galactopyranosyl conjugate of DOTA (1,4,7,10-
tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane).[27] 
99mTc-DTPA-GSA, a conjugate of galactosylated serum albumin 
(GSA) with 99mTc-DTPA (DTPA = 3,6,9-tris(carboxymethyl)-3,6,9-
triazaundecan-1,11-dioic acid), is useful in SPECT (single 
photon emission computed tomography) hepatic imaging to 
assess ASGPR in mice [28] and used clinically in humans. [29,30] 
Monocrystalline iron oxide nanoparticles (MION) conjugated to 
the bovine plasma protein asialofetuin (ASF), (MION-ASF),[31] 
arabinogalactan (AG)-coated ultra-small superparamagnetic 
iron oxide particles (USPIO), (AG-USPIO),[32,33] spin-labelled 
arabinogalactan,[34] and a Gd-DTPA conjugate of polylysine 
(PL) derivatized with galactosyl groups (Gd-DTPA-gal-PL), [35] 
have also been developed as potential contrast agents for 
liver MRI by targeting the hepatocyte ASGPR and tested in 
cells and mice. 
In this paper we report the synthesis and 
characterization of a series of multivalent lanthanideIII-
glycoconjugates, based on DOTA-monoamide functionalized 
chelators (Scheme 1). DOTA-like chelators are well known to 
form LnIII chelates of high thermodynamic and kinetic 
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stability, which is of crucial importance for in vivo 
applications.[36]  
The covalent binding of GdIII chelates to macro and 
biomolecules[7,8] and the formation of supramolecular 
assemblies[15] have been reported to slow down the tumbling 
rate of the paramagnetic chelates which leads then to higher 
relaxivities. In the present work, the in vitro relaxivity of 
the GdIII-glycoconjugates was measured and the parameters that 
influence relaxivity were determined. We hypothesised that 
the glycoconjugates-lectin association could substantially 
slow down the rotation and therefore enhance proton 
relaxivity of the GdIII-labelled glycoconjugates. This could 
be the basis of a new class of paramagnetic CAs targeted to 
lectins, both soluble and membrane-bound. In order to test 
this concept we studied the interaction of GdIII-
glycoconjugates in vitro with the model lectin Ricinus 
Communis Agglutinin (RCA) through relaxometric measurements. 
To our knowledge this is the first time that the interaction 
between a GdIII-glycoconjugate and a lectin is experimentally 
investigated in the context of MRI. 
 
Results and Discussion 
Synthesis of the ligands: We devised the synthesis of a series 
of glycoconjugates of metal complexes, which includes various 
galactose (Gal), glucose (Glc) and lactose (Lac) derivatives 
of different valencies, namely the monoderivatives 1 (DOTAGal, 
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DOTAGlc, DOTALac), the divalent glycoconjugates 2 (DOTAGal2, 
DOTAGlc2, DOTALac2) and the tetravalent glycoconjugate 3 
(DOTAGal4) (Scheme 1). 
We have devised a convergent synthesis for these ligands. A 
metal chelator block and a sugar block suitably functionalised 
were synthesised separately. Subsequent coupling afforded the 
fully protected glycoconjugates, which were then deprotected 
to give the final compounds 1, 2 and 3.  
The metal pro-chelator block 7 is a protected amino-
functionalized DOTA monoamide derivative (Scheme 2). 
As sugar block we used a carboxylic acid-functionalised 
glycodendrimer, prepared as illustrated for generation 1 (G1) 
dendromers 10 [37] (Scheme 3).  
Generation 2 (G2) dendromer 12 was prepared in a convergent 
way from diamine 9 and TFA salt 11a (Scheme 4).   
The synthesis of diamine 9 was accomplished by a 
modification of Roy´s original procedure [37] (Scheme 5). 
The standard DCC/HOBT (DCC=dicyclohexylcarbodiimide; 
HOBT=1-hydroxybenzotriazol) coupling procedure revealed 
successful for preparing fully protected monovalent 18, 
divalent 17 and tetravalent 16- glycoconjugates. A two-step 
deprotection, TFA/CH2Cl2 followed by KOMe/EtOH, afforded the 
fully deprotected monovalent 1, divalent 2 and tetravalent 3 
glycoconjugates (Schemes 6 and 7). 
The characterization of intermediate fully protected 
compounds, especially glycoconjugates 16, 17 and 18 by 1H NMR 
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spectroscopy proved difficult due to extensive broadening and 
overlapping of signals.  The assignment of the 1H and 13C NMR 
spectra from fully deprotected compounds in D2O revealed even 
more challenging, as experienced by other groups working with 
different types of multivalent glycoconjugates.[19,37] High 
resolution mass spectrometry (HRMS) confirmed the identity of 
the final compounds.  
NMR characterization of the glycoconjugate ligands in aqueous 
solution: The 1H NMR spectra of the DOTAGal (1a), DOTAGlc (1b), 
DOTALac (1c), DOTAGal2 (2a), DOTAGlc2 (2b), DOTALac2 (2c) and 
DOTAGal4 (3) ligands (10 mM) in D2O were obtained  in the pH 
0.90-9.50 range, at 25 oC, 60 oC and 80 oC and fully assigned 
using the DQF-COSY technique. The 1H shifts at pH 7.0 are 
listed in the Experimental section. 
In all cases, changing the pH did not affect the sugar 
proton resonances, but had a profound effect on the DOTA 
macrocyclic and pendant arm CH2 signals. The CH2 signals from 
all pendant arms except one remained sharp throughout the pH 
range, as well as the signals from the macrocyclic CH2 protons, 
which are very broad below pH 3, due to the rigidifying effect 
of the presence of internal hydrogen bonds.[38] These signals 
sharpen considerably and shift to low frequencies as the pH 
increases above 3.0, due to successive selective deprotonation 
of some of the nitrogens and carboxylate oxygens, destroying 
most of those internal hydrogen bonds. A temperature increase 
has a similar sharpening effect on those resonances.  
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The CH2 resonances of the bridging moieties are generally 
sharp, indicating flexibility, and have almost no pH 
dependence, with some exceptions. In DOTAX2 (X = Gal, Glc and 
Lac) and in DOTAGal4, the NCH2C(O) proton signals shift 
somewhat (eg.  from 4.06 ppm at pH 1.1  to 4.12 ppm at pH 5.2, 
for  DOTAGlc2) but broaden and disappear at pH > 5.5, while 
some broadening is also observed for the NCH2 protons close to  
the branching protonated nitrogen atoms. This indicates that an 
interaction occurs at high pH between these positively charged 
nitrogens and the negatively charged  deprotonated DOTA-
monoamide pendant carboxylate groups.  
NMR studies of some LnIII-glycoconjugates: The 1H NMR spectra of 
the paramagnetic complexes SmIII-DOTAGal, SmIII-DOTAGlc2, SmIII-
DOTALac2  and EuIII-DOTALac2 were obtained in D2O at 25 oC (see 
Figure 1 for EuIII-DOTALac2). For all the SmIII complexes and the 
EuIII complex, the protons of the sugar moieties and the 
bridging arms are hardly perturbed by the paramagnetic center, 
with very small broadenings and paramagnetic shifts smaller 
than 0.05 ppm (with the exception of the NCH2CH2 protons of the 
EuIII-DOTALac2 complex, with a paramagnetic shift of +0.30 ppm). 
This indicates that they have preferred solution conformations 
with the sugar and linker moieties extended away from the 
LnIII-binding chelate moiety, due to the r-6 and  r-3 dependency, 
respectively, of the dominant dipolar contributions to the 
paramagnetic relaxation and shift induced by the LnIII ion, 
where r is the LnIII-proton distance in the complex.[39] However, 
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the CH2 resonances within the macrocyclic ring and pendant arms 
of the derivatized DOTA moiety are strongly shifted, and 
somewhat broadened. These features show close similarities 
with the parent DOTA and related complexes.[39-42] These 
complexes can adopt two diastereomeric structures, the square 
antiprismatic (M) and the twisted square antiprismatic (m) 
structure, which differ in the layout of the coordinating arms 
relative to the macrocyclic ring, with a twist angle between 
the two planes formed by the four nitrogens and four oxygens 
in the coordination sphere of the LnIII of about 40o (M) and    
–20o (m). For the same LnIII complex, the paramagnetically 
shifted 1H resonances of the M isomer cover a spectral window 
about double of the m isomer.[40,41] The EuIII-DOTALac2 complex 
shows two sets of signals corresponding to M- and m- type 
structures, with a relative intensity ratio of about 3:1 
(Figure 1), similar to what has been found for other 
assymetric DOTA derivatives.[42] The paramagnetic centers are 
expected to cause a separate resonance for each of the protons 
of each isomer in the assymetrically substituted amide ligand, 
with a total of 24. All of these are seen for the M isomer, in 
the   + 33.5 to –16.6 ppm range, but only some for the m 
isomer, e.g. at ppm -8.8, -7.2, -6.0, -1.2. A comparison of 
the relative shifts of the M isomer of EuIII-DOTALac2 and EuIII-
DOTA[43]  allows the assignment of the resonances of this isomer 
to the types of protons present in the DOTA moiety of the 
glycoconjugate (ppm: -16.6, -15.5, -15.0, -14.8 for ac2; -14.6, 
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-12.5, -12.1, -11.4 for ax2; -10.6, -7.9, -7.6, -6.8 for ac1;  
-5.6, -4.8, -3.1, -2.9 for eq2; -1.9, -0.1, 0.0, +1.9 for eq1, 
+31.1, +31.4, +32.6, + 33.5 for ax1, Fig.1). In the present 
case, the orientation of the substituent did not lead to a 
doubling of these resonances as a consequence of the formation 
of two structural isomers, indicating that fast rotation about 
the amide bond occurs, similar to what has been found for 
other monosubstituted amide derivatives, but not in 
disubstituted ones.[42] 
 The signals are somewhat broadened at 25 oC due to M Ù m 
isomeric exchange,[41] but this exchange broadening effect is 
much more noticeable for the SmIII complexes, where only six 
broad resonances are detectable at + 7.2, + 4.2, + 1.6, + 1.4, 
+ 1.2 and –2.1 ppm, which, when compared with those of SmIII-
DOTA,[40] can be assigned, respectively, to the ac2, ax2, ac1, 
eq1, eq2 and ax1 protons of the M isomer. However, this 
broadening causes overlap of the four signals from each type 
of proton in the four chelate units, and does not allow 
observation of the m isomer. 
NMRD studies of the GdIII-glycoconjugates and their binding to 
RCA: The proton relaxivity of the GdIII complexes describes the 
efficiency of the magnetic dipolar coupling between the water 
proton nuclei and the paramagnetic metal ion, therefore it is 
a direct measure of the efficacy of the complex as a contrast 
agent. The paramagnetic ion enhances the relaxation rates of 
the bulk water protons by long-range and short-range 
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interactions (outer sphere and inner sphere relaxation, 
respectively). The inner sphere term is governed by the 
exchange rate of the inner sphere water molecule (kex), the 
rotational correlation time of the complex (τR), and the 
longitudinal and transverse electronic relaxation rates of the 
GdIII (1/T1e and 1/T2e). The outer sphere contribution to the 
overall proton relaxivity depends on the electron spin 
relaxation rates and the diffusion coefficient for the 
diffusion of a water proton away from a GdIII complex (see 
Appendix). [43]  
 The proton relaxivities have been measured for the GdIII 
glycoconjugates of the three types of sugars at three 
different temperatures (25, 37 and 60 °C) between 0.2 and 20 
MHz proton Larmor frequency. They are all characteristic of 
low molecular weight GdIII complexes. As a representative 
example we show the nuclear magnetic relaxation dispersion 
(NMRD) profiles of the divalent glucose derivative GdIII-
DOTAGlc2 (Figure 2). The NMRD curves of the two divalent 
derivatives of galactose and lactose, GdIII-DOTAGal2 and GdIII-
DOTALac2, respectively, can be found in the supporting 
information. The profiles have been fitted to the usual 
Solomon-Bloembergen-Morgan theory that relates the 
paramagnetic relaxation rates to the microscopic parameters of 
the GdIII complex (for equations see Appendix). As it has been 
pointed out previously, given the large number of factors 
influencing proton relaxivity, the parameters describing 
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relaxivity cannot be determined exclusively from the often 
featureless NMRD profiles. Therefore an independent access to 
some of the parameters is usually required. Water exchange 
rates have been determined on numerous GdIII chelates, 
including [Gd(DOTA)(H2O)]-, [Gd(DTPA)(H2O)]2- and their 
different amide derivatives. As a relatively general rule, it 
was found that the replacement of each carboxylate 
coordinating group of the poly(amino carboxylate) ligand by an 
amide function results in a decrease of the water exchange 
rate by a factor of 3-4.[43] This decrease is independent of the 
substituents on the amide group. The glycoconjugates studied 
here are all monoamide derivatives of DOTA4-. Therefore, based 
on the large body of available data on the water exchange on 
similar DOTA-monoamides, in the analysis of the NMRD profiles 
we fixed the rate as well as the activation enthalpy of the 
water exchange to usual values (kex298 = 1.2×106 s-1 and ∆H‡ = 
30.0 kJ mol-1). Moreover, the diffusion coefficient for the 
diffusion of a water proton away from a GdIII chelate (DGdH298) 
as well as its activation energy is not much dependent on the 
nature of low molecular weight complexes; hence in the fitting 
procedure these two parameters were also fixed to common 
values.[44] Consequently, in the analysis of the NMRD profiles 
we fitted the rotational correlation time, τR, its activation 
energy, ER, and the parameters describing the electron spin 
relaxation, i.e. the trace of the square of the transient 
zero-field-splitting (ZFS) tensor, ∆2, and the correlation time 
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for the modulation of the ZFS, τv. The parameters obtained for 
the three GdIII chelates are presented in Table 1.  
 The rotational correlation times calculated for the 
different glycoconjugates are all reasonable for small 
chelates, and as expected, increase with increasing molecular 
weight from the galactose and glucose derivatives to the 
larger size lactose conjugates.[43] As τR values dominate the 
high-field NMRD values, the relaxivities of these complexes at 
20 MHz and 25 oC are significantly higher than those previously 
found for smaller DOTA-monoamide complexes.[42,43,45] The 
parameters obtained for the electron spin relaxation of the 
GdIII complexes are also within the usual range for similar 
GdIII-DOTA monoamide chelates, with a significant increase of ∆2 
relative to the more symmetric GdIII-DOTA chelate, affecting 
the low-field NMRD values.[42,43,45,46]  Although in the last few 
years it has become evident that the simplified model of 
electron spin relaxation used here is not fully adequate to 
describe GdIII chelates,[47] the application of the novel 
theories requires EPR data in a large field range which was 
beyond the scope of the present study.    
The proton relaxivities of these small molecular weight 
chelates are limited by fast rotation. This is clearly shown 
by the temperature dependence of the profiles: proton 
relaxivities increase when the temperature decreases, thus the 
rotation slows down. 
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These glycoconjugates are capable of binding to lectins. In a 
solid phase competitive assay (ELLA, Enzyme-Linked Lectin 
Assay) we were able to verify a mini glycoside cluster effect 
in the binding of these glycoconjugates to PNA (Peanut 
agglutinin). [18, 48] 
The binding could considerably decrease the tumbling rate of 
the Gd(III)-glycoconjugates and thus enhance their proton 
relaxivity. We have performed proton relaxivity measurements 
in solutions of the GdIII-glycoconjugates in the presence of 
Ricinus Communis Agglutinin, RCA120 (MW=120 000) as model 
lectin. RCA120 is a S-S dimmer of two subunits. Each subunit 
(MW= 60 000) is a heterodimeric protein made of two S-S linked 
chains- A and B chains. The B chain is made of two globular 
domains, with a carbohydrate binding site, specific for 
terminal β-linked galactosides, per domain. The A chain has N-
glycosidase activity which inhibits protein synthesis. The two 
subunits are associated covalently by a S-S bond between the 
two A chains. The dimmer is further stabilised by contacts on 
the interface.[16,17]  
 Under the best available experimental conditions, the 
concentration of the RCA120 was 0.5 %, corresponding to a 0.04 
mM concentration (more concentrated solutions are not 
commercially available), whereas the concentration of the GdIII 
chelate was 1.0 mM (at lower concentrations of the 
paramagnetic species the relaxivity measurements become 
imprecise). Assuming an association constant of 104 [16] and two 
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independent binding sites on the RCA molecule, and that the 
spacing of the sugar terminals on the divalent glycoconjugates 
does not allow the simultaneous clustering of both sugars on 
the same molecule of RCA, in the best case scenario we would 
have two Gd-glycoconjugate units per RCA molecule, i.e. 
maximum 8 % of all the GdIII chelate would be bound to the 
protein. For all our systems we observed a slight increase 
(around 5 %) in proton relaxivity in a solution of 0.5 % 
RCA120. This relaxivity increase is not much higher than the 
error margin of the measurements, therefore we prefer not to 
interpret this result unambigously in terms of lectin binding. 
Although the bound species very likely has a higher proton 
relaxivity due to slower rotation, its concentration is too 
low and therefore a substantial increase in relaxivity is 
difficult to observe. A clear effect of the glycoconjugate-
lectin association on the in vitro proton relaxivity could 
only be observed with considerably higher concentrations of 
the lectin-bound GdIII complex. The only possibility to 
increase the percentage of bound Gd-species, and therefore the 
relaxivity, is to have a higher concentration of lectin in the 
assay, however the lectin availability is a limiting factor. 
The feasibility of in vivo MRI applications based on receptor 
binding in general depends on the concentration of the given 
receptor as well as on the relaxivity of the receptor-bound 
species. Targeted receptors in cells in general are usually 
present at concentrations within the range 10-9-10-13 mol/g of 
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tissue. [49] The minimal concentration of a contrast agent that 
is detectable by MRI (the concentration necessary to observe a 
signal enhancement) has been estimated between 5⋅10-7 mol/g for 
the low molecular weight Gd(HP-DO3A)(H2O) (r1=3.7 mM-1s-1) and 
1.9⋅10-10 mol/g for a 6th generation, Gd(DTPA)-loaded dendrimer 
(r1=5800 mM-1s-1 per dendrimer) or 1.6⋅10-11 mol/g for 
superparamagnetic iron oxide particles (r2=72 000 mM-1s-1 per 
particle) (HP-DO3A = 1,4,7-tris(carboxymethyl)-10-
hydroxypropyl-1,4,7,10-tetraazacyclo-dodecane).[50] In addition 
to receptor binding on the cell surface, receptor mediated 
endocytosis can lead to accumulation of the magnetic species 
inside the cell. With an efficient internalization mechanism, 
the concentration of the MRI contrast agent inside the cell 
can largely exceed what is expected solely by surface binding, 
thus it can help circumvent the problem of low MRI 
sensibility. Preliminary results of biodistribution studies 
with Wistar rats using 153Sm-labeled glycoconjugates of 
different valencies and sugar type indicate a specific hepatic 
uptake of the galactose and (to a less extent) lactose 
glycoconjugates through the ASGPR (results to be published 
separately). However, the feasibility of MR imaging based on 
the specific hepatic uptake of the GdIII glycoconjugates 
remains to be tested.  
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Conclusions 
Conjugating a small glycodendrimer ending with galactose 
unit(s) to a DOTA scaffold via an amide bond generates a new 
class of stable hydrophilic glycoconjugates. The 
glycodendrimer architecture was found suitable to vary the 
sugar type and valence in a interactive way from a reduced 
number of building blocks. 
The LnIII chelates of these glycoconjugates have predominant 
square antiprismatic solution structures of the coordinating 
DOTA moiety, with one inner-sphere water molecule. The 
flexibility of the glycodendrimer moiety in solution somehow 
limits the relaxivity of their GdIII complexes to values lower 
than expected from their molecular weight. However we 
envisaged that the lectin-glycoconjugate interaction could 
considerably slow down the tumbling rate and therefore 
increase the relaxivity of the GdIII chelates. Further studies 
are needed in order to unumbiguously verify this effect. Our 
results open the way for the study of GdIII-glycoconjugates as 
potential candidates for lectin-mediated molecular imaging 
agents.  
Experimental Section 
 
Materials and analysis: Chemicals were purchased from 
Sigma-Aldrich and used without further purification. Solvents 
used were of reagent grade and purified by usual methods. 
Reactions were monitored by TLC on Kieselgel 60 F254 (Merck) on 
aluminium support. Detection was by examination under UV light 
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(254 nm), by adsorption of iodine vapour and by charring with 
10% sulphuric acid in ethanol. Flash chromatography was 
performed on Kieselgel 60 (Merck, mesh 230-400). The relevant 
fractions from flash chromatography were pooled and 
concentrated under reduced pressure, T<40 oC. FAB mass spectra 
(positive mode) were recorded using a VG Autospec mass 
spectrometer with 3-nitrobenzyl alcohol (NBA) as matrix. 
NMR spectra: 1H NMR (1D and 2D) and 13C NMR spectra were run on 
a Varian Unity Plus 300 NMR spectrometer, operating at 299.938 
MHz and 75.428 MHz, for 1H and 13C, respectively. Chemical 
shifts (δ) are given in ppm relative to the CDCl3 solvent (1H, δ 
7.27; 13C 77.36) as internal standard. For 1H and 13C NMR 
spectra recorded in D2O, chemical shifts (δ) are given in ppm, 
respectively, relative to TSP as internal reference (1H, δ 0.0) 
and tert-butanol as external reference (13C, CH3  δ 30.29). 13C 
NMR spectra were proton broad-band decoupled using a 
decoupling scheme. The pD of the D2O solutions was adjusted 
with DCl or CO2-free NaOD and converted to pH values using the 
isotopic correction pH = pD-0.4. The pD values were measured on 
a HANNA pH-meter with a HI1310 combined electrode (HANNA 
instruments, Italy).  
NMRD measurements: The 1/T1 nuclear magnetic relaxation 
dispersion (NMRD) profiles of the water protons were obtained 
on a Spinmaster FFC fast cycling NMR relaxometer (Stelar), 
covering a continuum of magnetic fields from 5x10-4 to 0.47 T 
(corresponding to a proton Larmor frequency range of 0.022-20 
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MHz). The concentration of the GdIII solutions was determined 
by ICP (Perkin_Elmer Instruments, Optim 200 DV). 
Synthesis of monoalkylated cyclen (5): To an ice-cooled 
solution of cyclen (4.08 g, 23.7 mmol) in CH2Cl2 (50 cm3) was 
added drop wise over 30 minutes a solution of ethylbromoacetate 
(3.0 g; 18.0 mmol) in CH2Cl2 (30 cm3). After 2 hrs the reaction 
mixture was allowed to reach room temperature and further 
stirred for 24 hrs. The white precipitate was filtered of and 
the solvent was removed under reduced pressure to give a yellow 
oil. Purification (CH2Cl2/MeOH/NH3/H2O: 100% CH2Cl2->70:30:5:5) 
afforded the title compound (4.83 g, 79 % yield) as a white 
syrup. 1H NMR (300 MHz, CDCl3): δ= 1.27 (t, J= 7.2 Hz, 3H; CH3), 
2.84 (m; 8H), 2.95 (m, 8H), 3.49 (m; 2H), 4.16 (q, J= 7.2, 3H; 
C(O)OCH2). 
Synthesis of orthogonally alkylated cyclen (6): To a solution 
of monoalkylated cyclen (5) (2.94 g, 11.4 mmol) in MeCN (100 
cm3), K2CO3 (9.43 g, 68.3 mmol) was added. To this suspension a 
solution of tert-butylbromoacetate (6.66 g, 34.1 mmol) in MeCN 
(30 cm3) was added drop wise over 20 minutes. The suspension 
was vigorously stirred at room temperature for 4 hrs. The 
suspended solid was removed by filtration, the solvent was 
evaporated under reduced pressure, and the residue was purified 
by dry flash chromatography CH2Cl2/MeOH (100% CH2Cl2->20% MeOH) 
to give the title compound (5.72 g, 84% yield) as a white foam. 
1H NMR (300 MHz, CDCl3): δ= 1.15 (t, J= 7.2 Hz, 3H; 
C(O)OCH2CH3), 1.33, 1.34 and 1.35 (s, 27H; tertBu), 1.80-3.70 (we 
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observe a set of very broad multiplets with an integration 
corresponding to 24H), 4.04 (q, J= 7.2 Hz, 3H; C(O)OCH2); MS 
(FAB+, NBA): m/z (%): 639 (89) [M+K]+, 623 (100) [M+Na]+; HRMS 
(FAB+, NBA): m/z: Calcd. for C30H56N4NaO8 623.3996, found: 
623.3981 [M+Na]+.  
Synthesis of ethylenediamine-functionalised cyclen (7): 
Compound 6 (5.24 g, 8.72 mmol) was dissolved in neat 
ethylenediamine (3 cm3; 2.70 g, 44.9 mol) and the resulting 
solution was stirred at room temperature for 72 hrs. The 
ethylenediamine was removed under reduced pressure and the 
residue was dried under vacuum to give a light yellow foam. 
This was purified by dry flash chromatography CH2Cl2/MeOH (100% 
CH2Cl2->50% MeOH) to give the title compound (4.18 g, 68% 
yield) as a white foam.  1H NMR (300 MHz, CDCl3): δ= 1.46 (s, 
27H; tertBu), 1.80-3.84 (we observe a set of very broad signals 
with an integration corresponding to 30H), 8.18 (broad, 1H; 
C(O)NH); 13C NMR (75.6MHz, CDCl3): δ= 27.68 and 27.84 (Me), 
36.60 (CH2), 40.03 (CH2), 55.39 (CH2), 55.51 (CH2), 55.90 (CH2), 
81.61 and 81.70 (CMe3), 172.17 (C(O)), 172.27 (C(O)); MS (FAB+, 
NBA): m/z (%):  637 (100) [M+Na]+; HRMS (FAB+, NBA): m/z: Calcd. 
for C30H58N6NaO7  637.4265, found 637.4246 [M+Na]+.  
Synthesis of orthogonally protected amine (15): To an ice-
cooled solution of 3,3´-iminobis(propylamine) (14) (0.94 g, 
7.1 mmol) in dichloromethane (20 cm3) a solution of 
ethyltrifluoroacetate (2.24 g, 15.6 mmol) in dichloromethane 
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(20 cm3) was added drop wise over 1 hr. The reaction mixture 
was allowed to reach room temperature and further stirred for 
16 hrs. The solvent was removed under reduced pressure to give 
a colourless oil. TLC analysis (CH2Cl2/MeOH; 4:1) revealed a 
major spot and a small spot ninhydrin-positive). This material 
was used on the next reaction without further purification. 
The oil was redissolved in MeCN (50 cm3) and 
diisopropylethylamine (DIPEA) (0.92 g, 7.1 mmol) was added. 
tert-Butylbromoacetate (1.38 g, 7.1 mmol) was added drop wise 
over 5 minutes and the reaction mixture was stirred at room 
temperature for 6 hrs with formation of a white precipitate. 
The reaction mixture was filtered to remove the white pp and 
the solvent was removed under reduced pressure to give a light 
red oil. This material was purified by dry flash 
chromatography (CH2Cl2/MeOH; 100% CH2Cl2->10% MeOH) to give the 
title compound as a colourless oil (2.50 g, 81% yield over two 
steps).   1H NMR (300 MHz, CDCl3): δ= 1.40 (s, 9H; tertBu), 1.67 
(qt, J= 6.3 Hz, 4H; NCH2CH2), 2.50 (t, J= 6.3 Hz, 4H; NCH2), 
3.12 (s, 2H; NCH2C(O)), 5.39 (app q, J= 6.3 Hz, 4H; NCH2CH2CH2), 
8.40 (t(br), 2H; NHC(O)CF3); 13C NMR (75.6MHz, CDCl3): δ= 25.43 
(NCH2CH2), 27.75 (CH3), 38.07 (NCH2CH2CH2), 51.83 (NCH2), 55.76 
(NCH2C(O)), 81.98 (OC(CH3)3), 115.89 (q, J= 287 Hz, CF3), 157.34 
(q, J= 37.0 Hz, NHC(O)CF3), 171.18 (C(O)O tertBu). 
Synthesis of bis-amine (9): To a solution of compound 15 (3.10 
g, 7.1 mmol) in MeOH/H2O (50/20 cm3) Dowex1-X2-100-OH- resin (30 
cm3, wet resin) was added. The reaction mixture was shaken at 
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room temperature for 72 hrs. The resin was filtered off, 
washed with water and methanol, and the filtrate was 
concentrated under reduced pressure to give a yellow oil. This 
material was purified by dry flash chromatography 
(CH2Cl2/MeOH/H2O/NH3; 100% CH2Cl2-> 40:60:10:10) to give the 
title compound as a colourless thick oil (1.21 g, 69 % yield).  
1H NMR (300 MHz, CDCl3): δ= 1.36 (s, 9H; tertBu), 1.51 (qt, J=6.9 
Hz, 4H; NCH2CH2), 2.50 (t, J= 6.9 Hz, 4H; NCH2), 2.65 (t, J= 
6.9 Hz, 4H; NCH2CH2CH2), 3.09 (s, 2H; NCH2C(O)); 13C NMR (75.6 
MHz, CDCl3): δ= 27.93 (CH3), 30.64 (NCH2CH2), 40.15 (NCH2CH2CH2), 
51.77 (NCH2), 55.85 (CH2C(O)), 80.60 (C(CH3)3), 170.71 (C(O)).  
Synthesis of divalent peracetylated thioglycosides (10a, 10b, 
10c): Typical procedure- illustrated for 10a: To a solution of 
bis-amine 9 (0.95 g, 3.87 mmol) in ice-cooled dichoromethane 
(100 cm3) was sequentially added peracetylated 
(galactosylthio)propionic acid (8a) (3.55 g, 8.13 mmol), HOBT 
(1.23 g, 9.76 mmol) and DCC (1.67 g, 9.76 mmol) was added drop 
wise as a solution in dicloromethane (10 cm3). After 15 minutes 
the reaction mixture was removed from the ice bath and allowed 
to reach room temperature. The reaction mixture was further 
stirred at room temperature overnight. The precipitate 
dicyclohexylurea (DCU) was removed by filtration and washed 
with dichloromethane. The filtrate was concentrated under 
reduced pressure to give tick syrup. This material was taken 
into ethyl acetate (200 cm3) and sequentially washed with 
NaHCO3 (sat. sol.; 3x 100 cm3) and brine (100 cm3). The organic 
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phase was concentrated under reduced pressure to give a white 
foam. Purification by dry flash chromatography (CH2Cl2 /MeOH; 
100% CH2Cl2->50% MeOH) afforded the title compound as a white 
foam (4.02 g, 96 % yield). 1H NMR (300 MHz, CDCl3): δ= 1.47 (s, 
9H; tertBu), 1.64 (m, 4H; NCH2CH2), 1.99, 2.06, 2.16 (12H, OAc), 
2.51 (m, 8H; overlapping signals from NCH2 and  SCH2CH2), 2.91-
2.06 (m, 4H; SCH2), 3.14 (s, 2H; NCH2C(O)), 3.35 (app q, J = 
5.4 Hz, 4H; NCH2CH2CH2), 3.95 (app t, J= 6.3 Hz, 2H; H-6a), 
4.14 (m, 4H; H-6b+H-5), 4.57 (d, J= 9.9 Hz, 2H; H-1), 5.05 (dd, 
J= 9.9 and 3.3 Hz, 2H; H-3), 5.21 (app t, J= 9.9 Hz, 2H; H-2), 
5.44 (d, J= 3.3 Hz, 2H; H-4), 7.02 (m(br), 2H; C(O)NH); MS 
(FAB+, NBA): m/z (%): 1082 (100) [M]+; HRMS (FAB+, NBA): m/z: 
Calcd. for C46H72N3O22S2 1082.4049, found 1082.4038 [M+H]+.  
10b: Starting from deprotected bis-amine (9) (0.516 g, 2.10 
mmol) and peracetylated (glucosylthio)propionic acid  (8b) 
(2.02  g, 4.62  mmol), 10b was obtained as a white foam  (2.27 
g, 96 % yield). 1H NMR (300 MHz, CDCl3): δ= 1.46 (s, 9H; tertBu), 
1.62 (m, 4H; NCH2CH2), 2.00, 2.03, 2.04, 2.09 (12H, OAc), 2.51 
(m, 8H; overllaping signals from NCH2 and SCH2CH2), 2.81-3.03 
(m, 4H; SCH2), 3.14 (s, 2H; NCH2C(O)), 3.33 (m, 4H; NCH2CH2CH2), 
3.71 (m, 2H; H-5), 4.10-4.34 (m; 4H), 4.58 (d, J= 10.2 Hz, 2H; 
H-1), 5.0 (t, J= 10.2, 2H; H-2), 5.07 (t, J= 10.2, 2H; H-4), 
5.22 (t, J= 9.3, 2H; H-3), 7.06 (m(br), 2H; NHC(O)); MS (FAB+, 
NBA): m/z (%): 1083 (100) [M+H]+; HRMS (FAB+, NBA): m/z: Calcd. 
for C46H72N3O22S2  1082.4049, found 1082.4059 [M+H]+.  
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10c: Starting from deprotected bis-amine 9 (1.05 g, 4.28 mmol) 
and peracetylated (lactosylthio)propionic acid  (8c) (6.52 g, 
9.00 mmol), 10c was obtained  as a white foam (7.10 g, 97 % 
yield). 1H NMR (300 MHz, CDCl3): δ= 1.47 (s, 9H; tertBu), 1.68 
(m(br), 4H; NCH2CH2), 1.96, 2.03, 2.04, 2.05, 2.06, 2.13, 2.15 
(21H, OAc), 2.47 (m, 4H; SCH2CH2), 2.56-2.76 (m (br), 4H; NCH2), 
2.78-3.06 (m, 4H; SCH2), 3.35 (m; 6H), 3.62 (m, 2H; H-5), 3.87 
(m; 2H), 3.90 (m; 2H), 4.10 (m; 6H), 4.54 (d, J= 10.2, 2H; H-
1´), 4.61 (d, J= 10.8 Hz, 2H; H-1), 4.91 (t, J= 9.6, 2H; H-2), 
4.97 (dd, J= 10.2 and 3.3 Hz, 2H; H-3´), 5.11 (dd, J= 10.6 and 
7.5 Hz, 2H; H-2´), 5.19 (t, J= 9.3 Hz, 2H; H-3), 5.35 (d, J= 
3.3 Hz, 2H; H-4´), 7.02 (t(br), 2H; NHC(O); MS (FAB+, NBA): m/z 
(%): 1659 (48.6) [M]+; HRMS (FAB+, NBA): m/z: Calcd. for 
C70H104N3O38S2 1658.5739, found 1658.5671 [M+H]+. 
Synthesis of tetravalent peracetylated thiogalactoside 12: A 
solution of divalent thiogalactoside 10a (2.83 g, 1.25 mmol) 
was stirred overnight with CH2Cl2/TFA (3/1, 20 cm3). The solvent 
was removed under reduced pressure to give a light yellow foam, 
which was redissolved in DCM (20 cm3) and the solvent was 
removed under reduced pressure. This procedure was repeated 
several times and the material was further dried under vacuum 
to give a thick light yellow foam (11a). 1H NMR analysis 
revealed the disappearance of the signal at δ=1.47 assigned to 
the tert-butyl group. No further purification or 
characterisation was carried out on this material. All the 
material obtained (we assumed a 100 % yield on the deprotection 
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reaction) was dissolved in ice-cooled DCM (10 cm3) and titrated 
(pH paper) to pH 9-10 with DIPEA. To this solution was added a 
solution of deprotected bis-amine (9) (0.146 g, 0.595 mmol) in 
DCM (10 cm3), followed by HOBT (0.220 g, 1.49 mmol) and a 
solution of DCC (0.300 g, 1.49 mmol) in DCM (10 cm3) was added 
drop wise. The resulting mixture was stirred for 15 minute in 
an ice bath, allowed to reach room temperature and further 
stirred for 24 hrs. The precipitated DCU was removed by 
filtration and the solvent was removed under reduced pressure. 
The resulting oil was redissolved in ethyl acetate (200 cm3) 
and washed with NaHCO3 (sat. sol.; 3 x 50 cm3) and brine (50 
cm3). The solvent was removed under reduced pressure, and the 
residue was purified by dry flash chromatography (CH2Cl2/EtOH, 
100% CH2Cl2->20% EtOH) to give the title compound as a white 
foam (1.12 g, 83 % yield). 1H NMR (300 MHz, CDCl3), selected 
signals: δ= 1.46 (s, 9H; tertBu), 1.64 (m, 8H; NCH2CH2), 1.98, 
2.05, 2.06, 2.16 (48H; OAc), 2.55 (m; 20H), 2.86-3.10 (m; 16H), 
3.32 (m; 14 H), 3.98 (app t, J= 6.6 Hz, 4H; H-6a), 4.14 (m, 
8H; H-6b+H-5), 4.59 (d, J= 9.9 Hz, 4H; H-1), 5.06 (dd, J= 10.0 
and 3.4 Hz, 4H; H-3), 5.20 (app t, J= 9.9 Hz, 4H; H-2), 5.44 
(d, J= 2.4 Hz, 4H; H-4), 7.02 (br, 4H; C(O)NH); HRMS (ESI): 
m/z: Calcd. for C96H151N9O44S4  1130.9363, found 1130.9385 [M+2H]2+. 
Synthesis of fully protected monovalent glycoconjugates (18a, 
18b, 18c): Typical procedure- illustrated for 18a: A round 
bottomed flask was charged with ethylenediamine-functionalised 
cyclen (7) (0.375 g, 0.61 mmol), peracetylated 
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galactosylthiopropionic acid (8a) (0.292 g, 0.67 mmol) and HOBT 
(0.100 g, 0.67 mmol) in DCM (20 cm3). The reaction was 
initiated by adding drop wise a solution of DCC (0.140 g, 0.67 
mmol) in DCM (5 cm3). The reaction mixture was stirred in an 
ice bath for 15 minutes, allowed to reach room temperature and 
further stirred for 16 hrs. The precipitate DCU was filtered 
off, the filtrate was concentrated under reduced pressure and 
the resulting yellow foam was redissolved in EtOAc (100 cm3). 
The organic phase was washed sequentially with KHCO3 (sat. sol. 
3x50 cm3) and brine (50 cm3) and concentrated under reduced 
pressure to give a white foam. This material was purified by 
dry flash chromatography (CH2Cl2 /MeOH; 100% CH2Cl2->30% MeOH) 
to give the title compound as a white foam (0.580 g, 92 % 
yield). 1H NMR (300 MHz, CDCl3) for compounds 18a, 18b, 18c the 
signals from the cyclen moiety and from the ethylenediamine 
linker - N(CH2)2)N, NCH2C(O) and C(O)NH(CH2)2)NHC(O)) 
respectively, appear in the range of δ= 2.40-3.60 as a set of 
broad multiplets overlaped with signals from the sugar moiety. 
Selected signals: δ= 1.44 (27 H; tertBu), 1.96, 2.01, 2.04, 2.13 
(12 H; OAc), 4.15 (m, 3 H; H-5+H-6a+H-6b), 4.90 (d, J= 9.3 Hz, 
1 H; H-1), 5.11 (dd, J= 9.9 and 3.3, 1 H; H-3), 5.18 (t, J= 
9.9, 1 H; H-2), 5.43 (d, J= 3.3 Hz, 1H; H-4), 8.35 and 8.43 
(C(O)NH); MS (FAB+, NBA): m/z (%): 1056 (100)  [M+Na]+; HRMS 
(FAB+, NBA): m/z: Calcd. for C47H80N6O17NaS 1055.5198, found 
1055.5204 [M+Na]+.              
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18b: Starting from 7 (0.328 g, 0.534 mmol) and 8b (0.280 g, 
0.640 mmol) the title compound was obtained as a white foam 
(0.381 g, 69% yield). 1H NMR (300 MHz, CDCl3) selected signals: 
δ= 1.46 (27 H; tertBu), 1.98, 2.00, 2.05, 2.08 (12 H; OAc), 
4.04-4.38 (m; 2 H), 4.54 (d, J= 10.2  Hz, 1 H; H-1), 5.0 (t, J= 
10.2, 2H; H-2), 5.07 (t, J= 10.2, 2H; H-4), 5.22 (t, J= 9.3, 
2H; H-3), 8.7 and 8.9 (m(br), 2H; NHC(O)); MS (FAB+, NBA): m/z 
(%): 1082 (100) [M]+; HRMS (FAB+, NBA): m/z: Calcd. for 
C46H72N3O22S2  1082.4049, found 1082.4038 [M+H]+. 
18c: starting from 7 (0.186 g, 0.302 mmol) and 8c (0.240 g, 
0.332 mmol), the title compound was obtained was a white foam 
(0.358 g, 90% yield). 1H NMR (300 MHz, CDCl3) selected signald: 
δ= 1.45 (27H; tertBu), 1.96, 2.03, 2.05, 2.14 (21H; OAc), 4.73 
(d, J= 9.9 Hz, 1H; H-1), 5.35 (d, J= 3.0 Hz, 1H; H-4´), 8.80 
and 9.02 (br, 2H; NHC(O)); MS (FAB+, NBA): m/z (%): 1344 (68) 
[M+Na]+, 1343 (100) [M-H+Na]+; HRMS (FAB+, NBA): Calcd. for 
C59H96N6O25NaS  1343.6044, found 1343.6074 [M+Na]+. 
Synthesis of fully protected divalent (17a, 17b, 17c) and 
tetravalent (16) glycoconjugates: Typical procedure- 
illustrated for 17a: A solution of divalent thiogalactoside 
(10a) (0.480 g, 0.44 mmol) was stirred overnight with 
CH2Cl2/TFA (3/1, 12 cm3). The solvent was removed under reduced 
pressure to give a light yellow foam. This material was 
redissolved in DCM (10 cm3) and the solvent was removed under 
reduced pressure. This procedure was repeated several times and 
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further dried under vacuum. 1H NMR analysis revealed the 
disappearance of the signal at δ=1.47 assigned to the tert-
butyl group. This material was carried forward without further 
purification or characterisation. All the material obtained (we 
assumed a 100% yield on the deprotection reaction) was 
dissolved in ice-cooled DCM (5 cm3) and titrated (pH paper) to 
pH 9-10 with DIPEA. To this solution was added a solution of 
ethylenediamine-functionalised cyclen (7) (0.246 g, 0.40 mmol) 
in the DCM (5 cm3), HOBT (0.060 g, 0.53 mmol) and a solution of 
DCC (0.100 g, 0.53 mmol) in DCM (5 cm3) was added drop wise. 
The resulting mixture was stirred for 15 minute in the ice 
bath, allowed to reach room temperature and further stirred 
overnight. The precipitated DCU was filtered of and the solvent 
was removed under reduced pressure. The resulting oil was 
redissolved in ethyl acetate (50 cm3) and washed with KHCO3 
(sat. sol.; 3 x 50 cm3) and brine (50 cm3). The solvent was 
removed under reduced pressure, and the residue was purified by 
dry flash chromatography (CH2Cl2/EtOH, 100% CH2Cl2 -> 10% EtOH) 
to give the title compound as a white foam (0.593 g, 90 % 
yield). 1H NMR (300 MHz, CDCl3) for compounds 17a, 17b, 17c and 
16: the signals from the cyclen moiety and from the 
ethylenediamine linker- N(CH2)2)N, NCH2C(O) and 
C(O)NH(CH2)2)NHC(O) respectively, appear in the range of δ= 
1.40-3.70 as a set of broad multiplets overlaped with signals 
from the sugar moiety and from the dendrimer scafold; selected 
signals: 1.44 and 1.46 (s, 27H; tertBu), 1.62-1.64 (m, 4H; 
 31
NCH2CH2), 1.96, 2.04, 2.06, 2.14 (24H; OAc), 2.46-2.73 (m, 8H; 
overlapping signals from NCH2 and  SCH2CH2), 2.89-3.08 (m, 4H; 
SCH2), 3.28 (m; 6H), 3.95 (app t, J= 6.3 Hz, 2H; H6a), 4.14 (m, 
4H; H-6b+H-5), 4.57 (d, J= 9.9 Hz, 2H; H-1), 5.05 (dd, J= 9.9 
and 3.3 Hz, 2H; H-3), 5.21 (app t, J= 9.9 Hz, 2H; H-2), 5.44 
(d, J= 3.3 Hz, 2H; H-4), 7.02 (br, 2H; C(O)NH); MS (FAB+, NBA): 
m/z (%): 1082 (100) [M]+; HRMS (FAB+, NBA): m/z: Calc. for 
C46H72N3O22S2  1082.4049, found 1082.4038 [M+H]+. 
 17b: Starting from compound 7 (0.522 g, 0.85 mmol) and 
compound 10b (1.10 g, 1.02 mmol) the title compound was 
obtained (0.874 g, 63% yield) as a white foam. 1H NMR (300 MHz, 
CDCl3) selected signals: δ= 1.45 and 1.47 (s, 27H; tertBu), 1.68 
(m, 4H; NCH2CH2), 1.99, 2.02, 2.05, 2.09 (24H, OAc), 2.53 (m, 
4H; NCH2), 2.61 (m, 4H; SCH2CH2), 2.84-3.05 (m, 4H; SCH2), 3.09 
(s (br), 2H; NCH2C(O)), 3.27 (m, 4H; NCH2CH2CH2), 3.33 (m, 4H; 
NCH2CH2NH), 3.82 (ddd, J= 10.0, 4.3 and 2.2 Hz, 2H; H-5), 4.16 
(dd, J= 12.3 and 2.0 Hz, 2H; H-6a), 4.27 (dd, J= 12.3 and 4.5 
Hz, 2H; H-6b), 4.69 (d, J= 10.2 Hz, 2H; H-1), 4.98 (t, J= 10.2, 
2H; H-2), 5.08 (t, J= 9.9 Hz, 2H; H-4), 5.22 (t, J= 9.3 Hz, 2H; 
H-3), 7.88, 8.32 and 8.82 (m, 4H; NHC(O)); MS (FAB+, NBA): m/z 
(%): 1645 (100) [M]+; HRMS (FAB+, NBA): m/z: Calcd. for 
C72H119N9O28NaS2  1644.7504, found 1644.7455 [M+H+Na]+.  
 17c: Starting from compound 7 (0.31 g, 0.50 mmol) and compound 
10c (0.912 g, 0.55 mmol) the title compound was obtained (1.01 
g, 91% yield) as a white foam. 1H NMR (300 MHz, CDCl3) selected 
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signals: δ= 1.45 and 1.47 (27H; tertBu), 1.74 (m(br), 4H; 
NCH2CH2), 1.97, 2.03, 2.04, 2.06, 2.07, 2.13, 2.15 (42H; OAc), 
2.54 (m, 4H; SCH2CH2), 2.82-3.02 (m(br), 4H; NCH2), 3.08 (s; 
2H), 3.25-3.33 (m; 4H), 3.40-3.56 (m; 2H), 3.67 (m, 2H; H-5), 
3.81 (t, J= 9.4 Hz, 2H), 3.89 (t, J= 6.6 Hz, 2H), 4.11 (m, 8H), 
4.53 (d, J= 9.9, 2H; H-1´), 4.59 (d, J= 9.9 Hz, 2H; H-1), 4.92 
(t, J= 9.9, 2H; H-2), 4.95 (m, 2H; H-3´), 5.07 (dd, J= 7.8 and 
2.7 Hz, 2H; H-2´), 5.20 (t, J= 9.3 Hz, 2H; H-3), 5.35 (d, J= 
3.0 Hz, 2H; H-4´), 7.79, 8.30, 8.83 (br, 4H; NHC(O)); HRMS 
(ESI): m/z: Calcd. for C96H153N9O44S2  1099.9721, found 1099.9760 
[M+H+Na]+.  
Fully protected tetravalent glycoconjugate 16: Starting from 
compound 7 (0.126 g, 0.20 mmol) and compound (12) (0.452 g, 
0.20 mmol) the title compound was obtained as a white foam 
(0.402 g, 72 % yield). 1H NMR (300 MHz, CDCl3) selected 
signals: 1.45 and 1.46 (27H; tertBu), 1.62-1.64 (m, 8H; NCH2CH2), 
1.97, 2.04, 2.06, 2.15 (48H; OAc), 2.31 (m, (br)), 2.57 (m br), 
2.98 (m br), 3.93 (s), 3.47 (s), 4.02 (m, 4H; H-6a), 4.14 (m, 
8H; H-6b+H-5), 4.56 (d, J= 9.9 Hz, 4H; H-1), 5.06 (dd, J= 10.0 
and 3.4 Hz, 4H; H-3), 5.19 (app t, J= 9.9 Hz, 4H; H-2), 5.43 
(d, J= 2.7 Hz, 4H; H-4), 7.62, 8.44 (br, NHC(O)); HRMS (ESI): 
m/z: Calcd. for C122H199N15O50S4 1401.1181, found 1401.1210 
[M+2H]2+. 
Synthesis of fully deprotected monovalent (DOTAGal (1a), 
DOTAGlc (1b) and DOTALac (1c)), divalent (DOTAGal2 (2a), 
DOTAGlc2 (2b), DOTALac2 (2c)) and tetravalent (DOTAGal4 (3)) 
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glycoconjugates: Typical procedure- illustrated for DOTAGal2 
(2a) 
A solution of fully protected glycoconjugate (17a) (0.500 g, 
0.304 mmol) in DCM/TFA (3:1, 4 cm3) was stirred at room 
temperature for 24 hrs. The solvent was removed at reduced 
pressure, the residue was redissolved in DCM (20 cm3) and the 
solvent was evaporated at reduced pressure. This procedure was 
repeated several times to afford a light yellow foam that was 
further dried under vacuum. 1H NMR analysis (300 MHz, CDCl3) 
revealed complete deprotection of the tert-butyl groups. No 
further purification was judged necessary. This material was 
dissolved in ethanol (10 cm3) and adjusted to pH 9-10 with a 1 
M KOMe solution in ethanol. The resulting solution was stirred 
at room temperature for 16 hrs. The solution was adjusted to pH 
~1 (pH paper) with Amberlyte 15 resin. The resin was 
transferred into a column, washed with water and eluted with 
NH3 (aq., 0.5 M) solution. The relevant fractions were pooled 
and the solvent was evaporated at reduced pressure to give the 
title compound as a vitreous solid (0.29 g, 85 % yield) over 
two steps. 1H NMR(300 MHz, D2O, pH 7.0): δ= 4.50 (d, J= 9.0 Hz, 
2H; H-1), 3.55 (app t, 2H; H-2), 3.66 (app t, 2H; H-3), 3.74 
(dd, J= 9.4 and 3.3 Hz, 2H; H-4), 3.98 (app t, J= 3.3 Hz, 2H; 
H-5), 3.75 (m, 4H; H-6a + H-6b), 3.30 (m, 4H; C(O)NHCH2), 3.40 
(m, 8H; NCH2 + NCH2CH2CH2), 1.87 (m br, 4H; NCH2CH2), 2.63 (m, J= 
6.6 Hz, 4H; SCH2CH2), 3.01 (t, J= 6.6 Hz, 4H; SCH2), 3.82 (m, 
2H;  DOTA amide NCH2C(O)), 3.44 (s, 6H; DOTA acetate NCH2CO2-), 
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3.51, 3.20, 3.12, 2.80, 2.36, 2.23 (br, 16H; DOTA macrocycle 
NCH2); 13C NMR (75.6 MHz, D2O): δ= 23.76, 26.69, 36.15, 36.30, 
38.91, 39.42, 48.47 (cluster of signals), 53.27 (cluster of 
signals), 54.45, 56.41, 56.76, 58.85, 61.38, 68.90, 69.65, 
74.04, 79.01, 86.22 (C-1), 165.85, 169.78, 174.88, 180.14; MS 
(FAB+, NBA): m/z (%): 1156 (5) [M+H+K]+,  1119 (1) [M+H]+; HRMS 
(FAB+, NBA): m/z: Calcd. for C44H80N9O20S2, 1118.4961, found 
1118.4925 [M+H]+. 
DOTAGlc2 (2b): Starting from the fully protected compound (17b) 
(0.683g, 0.420 mmol) the title compound was obtained (0.356 g, 
76 % yield) over two steps as a vitreous solid. 1H NMR (300 
MHz, D2O, pH 7.0): δ= 4.55 (d, J= 9.9 Hz, 2H; H-1), 3.63 (app 
t, 2H; H-2), 3.69 (app t, 2H; H-3), 3.56 (dd, J= 12.3 and 2.1 
Hz, 2H; H-4), 3.91 (app t, 2H; H-5), 3.47 (m, 4H; H-6a + H-6b), 
3.30 (m, 4H; C(O)NHCH2), 3.40 (m, 8H; NCH2 + NCH2CH2CH2), 1.87 
(m br, 4H; NCH2CH2), 2.64 (m, 4H; SCH2CH2), 3.00 (t, J= 6.6 Hz, 
4H; SCH2), 3.82 (m, 2H; DOTA amide NCH2C(O)), 3.44 (s, 6H; DOTA 
acetate NCH2CO2-), 3.51, 3.20, 3.12, 2.80, 2.36, 2.23 (br,  16H; 
DOTA macrocycle NCH2); 13C NMR (75.6 MHz, D2O): δ= 26.57, 36.42, 
38.38, 38.99, 48.58, 48.78, 50.50, 52.15, 52.60, 56.44, 61.15, 
69.77, 71.07, 72.30, 77.31, 79.92, 85.75 (C-1), 169.83, 172.85, 
174.65, 178.82; MS (FAB+, NBA): m/z (%): 1141 (9) [M+Na]+, 1119 
(6) [M+H]+; HRMS (FAB+, NBA): m/z: Calcd. for C44H81N9O20S2  , 
1119.5039, found 1119.4978 [M+H]+. 
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DOTALac2 (2c): Starting from the fully protected compound (17c) 
(0.700 g, 0.314 mmol) the title compound was obtained (0.295 g, 
65 % yield) over two steps as a vitreous solid:          1H NMR 
(300 MHz, D2O, pH 7.0): δ= 4.42 (d, J= 7.8 Hz, 2H; H-1), 3.52 
(dd, J= 10.2 and 7.8 Hz, 2H; H-2), 3.63 (app t, 2H; H-3), 3.72 
(dd, 2H; H-4), 3.98 (d, J = 3.3 Hz, 2H; H-5), 3.70 (m, 4H; H-6a 
+ H-6b), 4.55 (d, J= 10.2 Hz, 2H; H-1’), 3.33 (app t, 2H; H-
2’), 3.64 (app t, 2H; H-3’), 3.72 (dd, 2H; H-4’), 3.88 (app t, 
2H; H-5’), 3.72 (m, 4H; H-6a’ + H-6b’), 3.30 (m, 4H; 
C(O)NHCH2), 3.40 (t, J= 6.0 Hz, 8H; NCH2 + NCH2CH2CH2), 1.88 (m 
br, 4H; NCH2CH2), 2.60 (m, J= 6.6 Hz, 4H; SCH2CH2), 2.96 (t, J= 
6.6 Hz, 4H; SCH2), 3.76 (m, 2H; DOTA amide NCH2C(O)), 3.32 (s, 
6H; DOTA acetate NCH2CO2-), 3.51, 3.20, 3.12, 2.80, 2.36, 2.23 
(br,  16H; DOTA macrocycle NCH2). (Gal unit: -H-1- H-6b ; Gluc 
unit: -H-1’- H-6b’ ); 13C NMR (75.6 MHz, D2O): δ= 23.83, 26.40, 
36.38, 38.31, 39.07, 48.60, 48.83, 48.98, 50.42, 52.19, 52.71, 
56.43, 57.56, 60.44, 61.18, 68.69, 71.08, 72.03, 72.64, 75.51, 
75.91, 78.37, 78.79, 85.53 (C-1’), 103.03 (C-1), 169.77, 
172.92, 174.70, 178.80; MS (FAB+, NBA): m/z (%): 1443 (5) 
[M+H]+, 1442 (7) [M]+, 1343 (17), 1321 (5); HRMS (FAB+, NBA): 
m/z: Calcd. for C56H100N9O30S2, 1442.6018. Found 1442.6017 [M+H]+. 
DOTAGal4 (3): Starting from the fully protected compound (16) 
(0.330 g, 0.118 mmol) the title compound was obtained (0.122 g, 
53 % yield) over two steps as a vitreous solid. 1H NMR (300 
MHz, D2O, pH 7.0): δ= 4.46 (d, J= 9.6 Hz, 4H; H-1), 3.49 (app 
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t, 4H; H-2), 3.63 (dd, J=9.3 and 3.0 Hz, 4H; H-3), 3.70 (dd, 
4H; H-4), 3.93 (app t, 4H; H-5), 3.70 (m, 8H; H-6a + H-6b), 
3.30 (m, 4H; C(O)NHCH2), 3.40 (m, 8H; NCH2CH2CH2NHC(O) + 
NCH2CH2CH2 NHC(O)), 1.93 (m, 4H; NCH2CH2CH2NHC(O)), 1.88 (m, 16H; 
NCH2CH2CH2NHC(O) + NCH2CH2CH2 NHC(O)), 1.70 (m, 8H; 
NCH2CH2CH2NHC(O)), 2.60 (m, 4H; SCH2CH2), 2.96 (app t, 4H; SCH2), 
3.74 (m, 2H; DOTA amide NCH2C(O)), 3.32 (s, 6H; DOTA acetate 
NCH2CO2-), 3.51, 3.40, 3.12, 2.80, 2.36, 2.23 (br, 16H; DOTA 
macrocycle NCH2); 13C NMR (75.6 MHz, D2O): δ= 24.87, 25.43, 
26.64, 36.50, 36.89, 37.24, 38.52, 38.80, 48.68 (cluster of 
signals), 50.58, 52.08, 52.31, 56.31, 56.46, 56.95, 61.36, 
68.93, 69.63, 74.05, 79.04, 86.24 (C-1), 169.83, 172.68, 
174.42, 178.51; MS (FAB+, NBA): m/z (%): 1999 (20) [M+K]+; HRMS 
(FAB+, NBA): m/z: Calcd. for C78H141N15O34S4K, 1998.8285, found 
1998.8325 [M+K]+. 
DOTAGal (1a): Starting from the fully protected compound 18a 
(0.502 g, 0.486 mmol) the title compound was obtained (0.205 g, 
60 % yield) over two steps as a vitreous solid. 1H NMR (300 
MHz, D2O, pH 7.0): δ= 4.50 (d,  J = 9.6 Hz, 1H; H-1), 3.55 (app 
t, J = 9.6 Hz, 1H; H-2), 3.65 (dd, J =9.3 Hz and 3.0 Hz, 1H; H-
3), 3.74 (m, 1H; H-4), 3.97 (app t, J = 3.3 Hz, 1H; H-5), 3.70 
(m, 2H; H-6a + H-6b), 3.46, 3.37 (m, 4H; NCH2  + NCH2CH2), 2.59 
(m, 2H; SCH2CH2), 2.99 (app t, 2H; SCH2), 3.81 (m, 2H; DOTA 
amide NCH2C(O)), 3.44 (s, 6H; DOTA acetate NCH2CO2-), 3.51, 
3.20, 3.12, 2.80, 2.36, 2.23 (br,  16H; DOTA macrocycle NCH2); 
13C NMR (75.6MHz, D2O): δ= 26.36, 36.54, 38.28, 38.66, 39.25, 
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48.49 (cluster of signals), 50.92, 51.97, 52.90 (cluster of 
signals), 56.01, 56.12, 56.54, 57.04, 58.79, 59.12, 61.32, 
61.38, 68.96, 69.69, 74.05, 79.09, 86.15 (C-1), 170.04, 172.53, 
174.60, 174.70, 174.79, 178.09, 180.16, 180.24; HRMS (FAB+, 
NBA): m/z: Calc. for C27H49N6O13S, 697.3078, found 697.3046 
[M+H]+. 
DOTAGlc (1b): Starting from the fully protected compound 18b 
(0.300 g, 0.290 mmol) the title compound was obtained (0.108 g, 
53 % yield) over two steps as a vitreous solid. 1H NMR (300 
MHz, D2O, pH 7.0): δ= 4.50 (d,  J = 9.6 Hz, 1H; H-1), 3.55 (app 
t, J = 9.6 Hz, 1H; H-2), 3.65 (dd J =9.3 Hz and 3.0 Hz, 1H; H-
3), 3.74 (m, 1H; H-4), 3.97 (app t, J = 3.3 Hz, 1H; H-5), 3.70 
(m, 2H; H-6a + H-6b), 3.46, 3.37 (m, 4H; NCH2  + NCH2CH2), 2.59 
(m, 2H; SCH2CH2), 2.99 (app t, 2H; SCH2), 3.81 (m, 2H; DOTA 
amide NCH2C(O)), 3.44 (s, 6H; DOTA acetate NCH2CO2-), 3.51, 
3.20, 3.12, 2.80, 2.36, 2.23 (br,  16H; DOTA macrocycle NCH2); 
13C NMR (75.6MHz, D2O) 26.27, 36.59, 38.72, 48.57, 50.94, 52.02, 
55.72, 56.23, 56.58, 61.14, 69.78, 72.38, 77.36, 80.02, 85.66 
(C-1), 170.02, 172.56, 174.70, 177.65; HRMS (FAB+, NBA): m/z: 
Calcd. for C27H49N6O13S, 697.3078, found 697.3068 [M+H]+. 
DOTALac (1c): Starting from the fully protected compound (18c) 
(0.310 g, 0.234 mmol) the title compound was obtained (0.098 g, 
49 % yield) over two steps as a vitreous solid.1H NMR (300 MHz, 
D2O, pH 7.0): δ= 4.50 (d,  J = 9.6 Hz, 1H; H-1), 3.55 (app t, J 
= 9.6 Hz, 1H; H-2), 3.65 (dd J =9.3 Hz and 3.0 Hz, 1H; H-3), 
3.74 (m, 1H; H-4), 3.97 (app t, J = 3.3 Hz, 1H; H-5), 3.70 (m, 
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2H; H-6a + H-6b), 3.46, 3.37 (m, 4H; NCH2  + NCH2CH2), 2.59 (m, 
2H; SCH2CH2), 2.99 (app t, 2H; SCH2), 3.81 (m, 2H; DOTA amide 
NCH2C(O)), 3.44 (s, 6H; DOTA acetate NCH2CO2-), 3.51, 3.20, 
3.12, 2.80, 2.36, 2.23 (br,  16H; DOTA macrocycle NCH2); 13C NMR 
(75.6 MHz, D2O, pH 7.0): δ= 26.19, 26.37, 27.61, 36.58, 38.70, 
48.56, 50.94, 52.04, 56.13, 56.20, 56.54, 61.22, 61.35, 68.76, 
69.02, 69.73, 71.15, 72.12, 72.70, 74.10, 75.53, 75.92, 78.32, 
78.84, 79.13, 85.50, 86.19 (C-1’), 103.06 (C-1), 170.01, 
172.58, 174.67, 174.73, 174.73, 178.16; HRMS (FAB+, NBA): m/z: 
Calcd. for C33H59N6O18S, 859.3606, found 859.3644 [M+H]+. 
Preparation of LnIII-glycoconjugates for NMR: The LnIII-
glycoconjugates were prepared by adding a slight excess (1.1 
eq.) of an aqueous solution of  LnCl3 to an aqueous solution of 
the glycoconjugate. The pH of the solution was slowly adjusted 
to pH 5 with KOH (aq) and the solutions were stirred at 70 oC 
for eight hours. The final pH was adjusted to 7 with KOH (aq) 
and any precipitate was filtered off. The solution was 
concentrated and purified by gel filtration with Sephadex G10, 
eluting with water. The relevant fractions were pooled and 
freeze dried to afford the LnIII complexes. 
Preparation of GdIII-glycoconjugates for NMRD: The 1/T1 
nuclear magnetic relaxation dispersion (NMRD) profiles of the 
water protons at 25, 37 and 60 oC were obtained on 2.52-4.63 
mM GdIII solutions. The concentration of the GdIII solutions 
was determined by ICP. The concentration of the DOTA-
derivated glycoconjugates was determined from the pH-
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potentiometric titration curves in the presence of a 50-fold 
excess of CaCl2, with TMAOH. The solutions of the GdIII-
glycoconjugates  were prepared by adding appropriate 
quantities of  the glycoconjugates to an aqueous solution of 
gadolinium perchlorate (3-5% glycoconjugate excess). The 
GdIII-glycoconjugate solutions were freeze dried and diluted 
with 25 mM phosphate buffer (pH 7.4). The GdIII concentrations 
were verified by ICP measurement.  
 
Acknowledgments 
This work was performed within the framework of the EU COST 
Action D18 “Lanthanide chemistry for diagnosis and therapy”. 
The work was supported by the Foundation of Science and 
Technology (F.C.T.), Portugal (project POCTI/QUI/47005/2002) 
and FEDER. J.P. André would like to acknowledge Prof. H. R. 
Mäcke for the support he received during his sabbatical leave. 
É. Tóth and A. E. Merbach acknowledge the Swiss National 
Science Foundation and the Swiss Federal Office for Education 
and Science for financial support. The authors are grateful to 
László Burai for his help in the NMRD measurements. 
 
Supporting Information: Tables S1-S3: Proton relaxivities of 
GdIII-DOTAGlc2, GdIII-DOTA Lac2 and GdIII-DOTAGal2, respectively. 
Figs. S1-S2. Variable temperature NMRD profiles of GdIII-DOTA-
Lac2  and GdIII-DOTAGal2, respectively.  
 
Appendix 
 
 40
NMRD: The measured proton relaxivities (normalized to 1 mM 
GdIII concentration) contain both inner and outer sphere 
contributions:  
r r r1 1is 1os= +            (1) 
The inner sphere term is given by Equation (2), where q is the 
number of inner sphere water molecules.  
r
q
T1is 1m
H
m
= × × +
1
1000 5555
1
. τ         (2) 
The longitudinal relaxation rate of inner sphere protons, 
1/T1mH is expressed: 
( )2 2 2 2S I d1H d2H6 2 2 2 2
GdH I d1H S d2H1m
1 2 3 71
15 4 1 1
o
H S SrT
µ γ γ τ τ
π ω τ ω τ
⎡ ⎤⎛ ⎞= + +⎜ ⎟ ⎢ ⎥+ +⎝ ⎠ ⎣ ⎦
h     (3) 
Here rGdH is the effective distance between the GdIII electron 
spin and the water protons, ωI is the proton resonance 
frequency and τdiH is given by Equation (4), where τR is the 
rotational correlation time of the GdIII-Hwater vector:  
eRmd
1111
iiH T
++= τττ  i = 1 , 2       (4) 
The τR rotational correlation time is assumed to have simple 
exponential temperature dependence with an ER activation 
energy:  
⎭⎬
⎫
⎩⎨
⎧ ⎟⎠
⎞⎜⎝
⎛ −=
15.298
11exp R298RR TR
Eττ         (5) 
The electron spin relaxation rates, 1/T1e and 1/T2e for metal 
ions in solution with S>1/2 are mainly governed by a transient 
zero-field-splitting mechanism (ZFS).[51] In Equations (6-7) ∆2 
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is the trace of the square of the transient zero-field-
splitting tensor, τv is the correlation time for the modulation 
of the ZFS with the activation energy Ev, and ωs is the electron 
spin Larmor frequency: 
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E
R T
1 1
29815
        (8) 
The outer sphere contribution is described by Equation (9), 
where NA is the Avogadro constant, and Jos is a spectral 
density function.  
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  j = 1, 2         (10) 
A value of 3.6 Å was used for aGdH. For the temperature 
dependence of the diffusion coefficient for the diffusion of a 
water proton away from a GdIII complex, DGdH, we assume a 
exponential temperature dependence, with an activation energy 
EDGdH:  
298 DGdH
GdH GdH
1 1exp
298.15
ED D
R T
⎧ ⎫⎛ ⎞= −⎨ ⎬⎜ ⎟⎝ ⎠⎩ ⎭       (11) 
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Legends of Figures 
 
Figure 1.  1H NMR spectrum  of  EuIII-DOTALac2 in D2O, pH 7.0, 
T=25 oC. 
 
Figure 2.  Variable temperature NMRD profiles for GdIII-
DOTAGlc2. T = 25 oC (triangles); 37 oC (squares) and 60 oC 
(circles). The lines represent the least squares fit to the 
experimental data points as described in the text. 
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Table 1 - Parameters obtained from the analysis of the NMRD 
profiles for the GdIII-glycoconjugates.  
 
 DOTAGal2(2a) DOTAGlc2(2b) DOTALac2 (2c) 
kex298/106 s-1 1.2a 1.2a 1.2a 
∆H‡ /kJ mol-1 30.0a 30.0a 30.0a 
τrH298/ps 242±6 261±8 306±10 
ERH/kJ mol-1 28.3±0.3 27.2±0.2 29.9±0.2 
τv298 /ps  35±2 39±3 33±5 
Ev/kJ mol-1[g] 1a 1a 1a 
∆2/1020 s-2 0.10±0.02 0.10±0.01 0.12±0.02 
DGdH298/10-10 m2s-1 24.0a 24.0a 24.0a 
EDGdH /kJ mol-1 20a 20a 20a 
 
a. Underlined parameters have been fixed in the fit. 
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Keywords: asialoglycoprotein receptor, liver targeting, 
lectins, glycoconjugates, lanthanideIII macrocycles, gamma-
scintigraphy, MRI  
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Scheme 1: Structure of monovalent (1), divalent (2) and 
tetravalent (3) glycoconjugate ligands. 
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Scheme 2: a) BrCH2C(O)OEt, CH2Cl2; b) BrCH2C(O)OtertBu/ 
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Scheme 3: a) DCC/HOBT, CH2Cl2; b) TFA/CH2Cl2 (1:3). 
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Scheme 4: a) i. DIPEA/CH2Cl2, ii. DCC/HOBT, CH2Cl2; 
b) TFA/CH2Cl2 (1:3). 
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Scheme 5: a) i. CF3C(O)OEt, CH2Cl2; ii. 
BrCH2C(O)OtertBu/DIPEA, CH3CN; b) Dowex 1X2-100-OH-, 
CH3OH/H2O. 
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Scheme 6: a) DCC/HOBT, CH2Cl2; b) i. TFA/CH2Cl2 ii. 
KOMe/EtOH iii. Amberlist 15, elution with NH3(aq).
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Scheme 7: a) i. DIPEA/CH2Cl2, ii. DCC/HOBT, CH2Cl2; b) i. 
TFA/CH2Cl2 (1:3) ii. KOMe/EtOH iii. Amberlist 15, elution with 
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Figure 1.  1H NMR spectrum  of  EuIII-DOTALac2 in D2O, pH 7.0, 
T= 25 oC. 
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Figure 2.  Variable temperature NMRD profiles for GdIII-
DOTAGlc2. T=25°C (triangles); 37°C (squares) and 60°C 
(circles). The lines represent the least squares fit to the 
experimental data points as described in the text. 
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Table S1. Proton relaxivities of GdIII-DOTAGlc2. 
 
 
Frequency 
(MHz) 
60 °C  Frequency 
(MHz) 
25 °C  Frequency 
(MHz) 
37 °C  
15.998 4.790 10.900 8.754 15.998 7.185
10.853 5.025 7.360 9.378 10.853 6.913
7.360 5.497 4.990 10.429 7.360 7.686
4.991 6.141 3.380 10.258 4.991 8.464
3.384 6.880 2.300 11.167 3.384 9.124
2.296 7.343 1.560 11.734 2.296 9.879
1.557 7.661 1.060 12.160 1.557 10.616
1.057 7.962 0.717 12.302 1.057 10.856
0.717 8.025 0.486 12.472 0.717 10.808
0.486 7.991 0.330 12.813 0.486 11.341
0.330 8.069 0.223 12.756 0.330 11.084
0.223 8.398 0.151 13.012 0.223 10.917
0.151 8.296 0.103 12.614 0.151 11.085
0.103 8.197 0.070 12.699 0.103 10.975
0.070 8.463 0.047 12.643 0.070 11.180
0.047 8.232 0.032 12.785 0.047 11.472
0.032 8.075 0.022 12.841 0.032 11.392
0.022 8.120 0.015 12.926 0.022 11.320
0.015 8.447 0.010 12.756 0.015 11.384
0.010 8.095 18.000 8.470 0.010 11.305
18.000 4.485 20.000 8.427 18.000 6.599
20.000 4.499  20.000 6.585
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Table S2. Proton relaxivities of GdIII-DOTA Lac2. 
 
 
Frequency 
(MHz) 
25 °C  Frequency 
(MHz) 
37 °C Frequency 
(MHz) 
60 °C  
15.998 9.170 15.998 7.306 15.998 5.061
10.853 9.786 10.853 7.415 10.853 5.399
7.360 9.157 7.360 8.083 7.360 5.820
4.991 10.400 4.991 8.895 4.991 6.406
3.384 10.637 3.384 9.327 3.384 6.890
2.296 11.571 2.296 10.135 2.296 7.506
1.557 12.112 1.557 10.582 1.557 7.651
1.057 12.582 1.057 11.029 1.057 8.318
0.717 12.848 0.717 11.352 0.717 7.987
0.486 12.828 0.486 11.362 0.486 8.250
0.330 13.326 0.330 11.243 0.330 8.164
0.223 13.075 0.223 11.229 0.223 8.087
0.151 13.337 0.151 11.544 0.151 8.523
0.103 13.150 0.103 11.556 0.103 8.328
0.070 13.054 0.070 11.557 0.070 8.390
0.047 13.158 0.047 11.304 0.047 8.666
0.032 13.306 0.032 11.209 0.032 8.534
0.022 13.577 0.022 11.476 0.022 8.595
0.015 13.198 0.015 11.656 0.015 8.290
0.010 0.010 11.229 0.010 8.307
18.000 8.875 18.000 7.023 18.000 4.785
20.000 8.934 20.000 6.905 20.000 4.756
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Table S3. Proton relaxivities of GdIII-DOTAGal2. 
 
 
Frequency 
(MHz) 
25 °C Frequency 
(MHz) 
37 °C Frequency 
(MHz) 
60 °C 
15.998 8.671 15.998 6.334 15.998 4.540
10.853 8.509 10.853 6.821 10.853 4.710
7.360 9.146 7.360 7.233 7.360 5.556
4.991 9.796 4.991 8.473 4.991 6.214
3.384 11.012 3.384 8.789 3.384 6.607
2.296 11.913 2.296 9.778 2.296 7.190
1.557 12.319 1.557 10.322 1.557 7.528
1.057 12.468 1.057 10.352 1.056 7.520
0.717 13.048 0.717 10.571 0.717 7.774
0.486 13.287 0.486 10.640 0.486 8.008
0.330 12.857 0.330 11.060 0.330 7.845
0.223 12.920 0.223 10.860 0.154 7.996
0.151 12.788 0.151 10.922 0.103 7.937
0.103 13.095 0.103 11.106 0.070 8.300
0.070 12.907 0.070 11.053 0.032 8.300
0.047 13.019 0.047 11.276 0.015 7.937
0.032 13.353 0.032 10.891 0.010 7.991
0.022 13.000 0.022 10.724 18.000 4.490
0.015 12.997 0.015 10.907 20.000 4.382
0.010 13.001 0.010 10.987  
18.000 8.321 18.000 6.211  
20.000 8.288 20.000 6.178  
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Figure S1: Variable temperature NMRD profiles of GdIII-DOTA-
Lac2. T=25°C (triangles);  37°C (squares) and 60°C (circles). 
The lines represent the least squares fit to the experimental 
data points as described in the text. 
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Figure S2: Variable temperature NMRD profiles of GdIII-DOTAGal2. 
T=25°C (triangles);  37°C (squares) and 60°C (circles). The 
lines represent the least squares fit to the experimental data 
points as described in the text. 
 
